Prevention of Implanted Central Venous Port Erosion with Prophylactic Mesh Tissue Augmentation

D. Palange,Dare V. Ajibade,S. Bonne,Anastasia Kunac

DOI: https://doi.org/10.1177/000313481708300927

2017-09-01

The American Surgeon

Abstract:Implanted central venous ports (ICVPs) are essential in the long-term treatment of sickle cell anemia patients with frequent vaso-occlusive crisis. ICVPs provide reliable vascular access for aggressive resuscitation, frequent transfusion, and erythrocytapheresis. Although a rare complication, ICVP erosion causes significant patient anxiety and leads to an associated delay in care with potentially life-threatening consequences. Such events further strain the resources of the healthcare system and increase the overall cost of care. The addition of a prophylactic biologic mesh for patients at risk for subcutaneous port erosion improves the integrity of the skin and subcutaneous tissues. The addition of prophylactic biologic mesh tissue augmentation at the time of ICVP placement potentially decreases the incidence of port erosion thereby improving care and decreasing health care cost. The patient is a 31-year-old African American male with a past medical history of sickle cell anemia and frequent vaso-occlusive crises, which include acute chest syndrome, bilateral avascular necrosis of the femoral heads, transfusion, and analgesic medication dependence as well as pain crises in bilateral knees, hips, and spine. Theses frequent vaso-occlusive crises have culminated in multiple emergency room visits and hospital admissions. These admissions, often require aggressive resuscitation, intravenous pain control, and transfusion of blood products. A reliable and durable venous access is paramount to efficient management of a vaso-occlusive crisis. This patient’s first implanted central venous port was placed in 2010. Since then, the patient’s clinical course has been fraught with multiple port erosions and subsequent central catheter–related bloodstream infections. Since 2010, the patient has experienced four episodes of port site erosion with subsequent replacement. Each episode results in delay of care, enormous patient anxiety, and further drain of a fragile health care system. The patient presented to outpatient clinic in August 2016 with erosion of the most recent ICVP (Fig. 1). The patient was at a significant risk of sepsis secondary to erosion and, in addition, beleaguered with both physical and emotional distress from interruption in care. Thus, this problem compels an innovative approach to replace the eroded port and reduce the risk of future occurrence. A prophylactic tissue augmentation with addition of a dermal matrix was then proposed. Alloderm, an acellular human dermal matrix was selected for this purpose. The patient was taken to the operating room in August of 2016 and the exposed ICVP was removed. A PowerPort VUE MRI implantable port in the left subclavian vein was used as a replacement. A 3 · 7-cm Alloderm Regenerative Tissue Matrix was cut to size and sutured within the 5 · 5-cm subcutaneous pocket on the left anterior chest wall. The Alloderm biologic mesh was used to cover the superficial aspect of the ICVP, adding an additional layer of protection and increasing the subcutaneous depth (Fig. 2). The port was tested through the Alloderm biological mesh and was found to be functional. Since placement, the patient has undergone greater than 15 separate admissions for sickle cell crisis without any catheter dysfunction or signs of erosion of ICVP. Although a rare complication with an estimated rate between <1 and 10 per cent,1 erosion of an ICVP can be highly distressing. These events are not only financially taxing but also imperil the psychosocial and clinical outcome variables of affected patients and their caregivers. The use of a prophylactic biological mesh in patients deemed high risk for erosion could potentially avoid the psychological stress of port erosion as well as the financial burden associated with Address correspondence and reprint requests to David Palange, D.O., Department of Surgery, Rutgers New Jersey Medical School, 185 South Orange Avenue, G level – General Surgery, Newark, NJ 07103. E-mail: dcp114@njms.rutgers.edu.